EP1496076A4 - Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff - Google Patents

Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff

Info

Publication number
EP1496076A4
EP1496076A4 EP03709581A EP03709581A EP1496076A4 EP 1496076 A4 EP1496076 A4 EP 1496076A4 EP 03709581 A EP03709581 A EP 03709581A EP 03709581 A EP03709581 A EP 03709581A EP 1496076 A4 EP1496076 A4 EP 1496076A4
Authority
EP
European Patent Office
Prior art keywords
derivate
preparation
hydrophilic polymer
above compound
type branch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03709581A
Other languages
English (en)
French (fr)
Other versions
EP1496076A1 (de
EP1496076B1 (de
Inventor
Shishan Ji
Dequan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Jiankai Technology Co Ltd
Original Assignee
Beijing Jiankai Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Jiankai Technology Co Ltd filed Critical Beijing Jiankai Technology Co Ltd
Publication of EP1496076A1 publication Critical patent/EP1496076A1/de
Publication of EP1496076A4 publication Critical patent/EP1496076A4/de
Application granted granted Critical
Publication of EP1496076B1 publication Critical patent/EP1496076B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP03709581A 2002-03-13 2003-03-12 Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff Expired - Lifetime EP1496076B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN0200147 2002-03-13
WOPCT/CN02/00147 2002-03-13
PCT/CN2003/000179 WO2003076490A1 (en) 2002-03-13 2003-03-12 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound

Publications (3)

Publication Number Publication Date
EP1496076A1 EP1496076A1 (de) 2005-01-12
EP1496076A4 true EP1496076A4 (de) 2006-06-21
EP1496076B1 EP1496076B1 (de) 2007-07-25

Family

ID=27792878

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03709581A Expired - Lifetime EP1496076B1 (de) 2002-03-13 2003-03-12 Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff

Country Status (9)

Country Link
US (3) US8003089B2 (de)
EP (1) EP1496076B1 (de)
JP (1) JP4272537B2 (de)
CN (1) CN1243779C (de)
AT (1) ATE368066T1 (de)
AU (1) AU2003221291A1 (de)
DE (1) DE60315145T2 (de)
ES (1) ES2291620T3 (de)
WO (1) WO2003076490A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
JP4272537B2 (ja) * 2002-03-13 2009-06-03 北京鍵▲凱▼科技有限公司 Ｙ型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物
BR0314227A (pt) 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
DE10326303A1 (de) * 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
JP5191729B2 (ja) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
US7858080B2 (en) 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
AU2006248166B2 (en) * 2005-05-20 2012-11-01 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
AU2006304856A1 (en) * 2005-10-21 2007-04-26 Synageva Biopharma Corp. Glycolated and glycosylated poultry derived therapeutic proteins
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
EP2089052A4 (de) * 2006-05-24 2011-02-16 Peg Biosciences Peg-linker-verbindungen und ihre biologisch wirksamen konjugate
CN101168594B (zh) * 2006-10-24 2011-07-27 北京键凯科技有限公司 寡肽为骨架的聚乙二醇活性衍生物、其制备方法及与药物分子的结合物
CN101125207B (zh) * 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
US20100203066A1 (en) * 2007-08-20 2010-08-12 Enzon Pharmaceuticals, Inc. Polymeric linkers containing pyridyl disulfide moieties
KR101483814B1 (ko) * 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
AU2007358605B8 (en) * 2007-09-04 2012-02-02 Biosteed Gene Expression Tech. Co., Ltd. Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
US8530417B2 (en) * 2007-12-29 2013-09-10 Biosteed Gene Expression Tech Co. Ltd. Y-shaped polyethylene glycol modified G-CSF, the preparation and use thereof
US9840546B2 (en) * 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
CN101701068B (zh) * 2009-10-30 2011-09-21 北京化工大学 一种pH响应性的Y型药物输送材料及其制备方法
JP2011105792A (ja) * 2009-11-12 2011-06-02 Japan Science & Technology Agency ブロックコポリマー、ブロックコポリマー−金属錯体複合体、及びそれを用いた中空構造体キャリア
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
US20140073778A9 (en) 2010-07-09 2014-03-13 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
US20140088298A9 (en) 2010-07-09 2014-03-27 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
WO2012004007A1 (en) 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
EP2590678A1 (de) 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Konjugate mit hydroxyalkylstärke und einem zytotoxischen mittel sowie verfahren zu ihrer herstellung
JP2014503187A (ja) 2010-10-29 2014-02-13 ノクソン ファーマ エージー 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用
CN103083680B (zh) * 2011-11-07 2014-12-24 北京键凯科技有限公司 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物
JP5999659B2 (ja) * 2011-12-14 2016-09-28 国立大学法人 筑波大学 新規分岐ポリエチレングリコール及びその用途
WO2014114262A1 (zh) * 2013-01-28 2014-07-31 天津键凯科技有限公司 水溶性聚合物-氨基酸寡肽-药物结合物及其制备方法和用途
CN103965458B (zh) * 2013-01-28 2017-02-15 天津键凯科技有限公司 聚乙二醇‑氨基酸寡肽‑达沙替尼结合物及其药物组合物
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
CN104109235B (zh) * 2014-05-30 2017-07-18 厦门赛诺邦格生物科技股份有限公司 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质
CN106146325B (zh) * 2015-04-24 2019-01-29 北京键凯科技股份有限公司 一种y型多缩乙二醇衍生物及其制备方法
CN107446908A (zh) * 2016-06-01 2017-12-08 湖南华腾制药有限公司 分支型聚乙二醇修饰的l‑门冬酰胺酶及其制备方法
CN106750250B (zh) * 2016-12-21 2019-04-23 沈阳化工大学 以氨基酸作为连接臂的聚乙二醇齐墩果酸衍生物及其制备方法和应用
CN108530637B (zh) * 2017-03-05 2021-03-30 厦门赛诺邦格生物科技股份有限公司 一种单一功能化支化聚乙二醇的制备方法
WO2018177055A1 (zh) * 2017-03-30 2018-10-04 北京键凯科技股份有限公司 一种y型分支的亲水性聚合物羧酸衍生物的制备方法
CN108659227B (zh) * 2017-03-30 2020-11-06 北京键凯科技股份有限公司 一种y型分支的亲水性聚合物羧酸衍生物的制备方法
CN108530642B (zh) * 2017-11-24 2021-01-15 四川大学 可生物降解的三嵌段杂臂星形双亲性高分子材料及其制备方法
CN109400868B (zh) * 2018-11-30 2021-01-15 吉林化工学院 一种聚乙二醇单苯甲醚化合物的合成方法
CA3193273A1 (en) 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer
CN112898561A (zh) * 2021-01-27 2021-06-04 大连理工大学 马来酰亚胺封端聚苯醚及其制备方法
EP4509544A4 (de) 2022-04-12 2025-07-02 Xiamen Sinopeg Biotech Co Ltd Nichtlineares pegyliertes lipid mit tertiärem amin und anwendung davon
CN117510828A (zh) 2022-07-28 2024-02-06 厦门赛诺邦格生物科技股份有限公司 一种含氨基酸残基的三臂聚乙二醇衍生物
WO2024164213A1 (zh) 2023-02-09 2024-08-15 谢彦晖 聚乙二醇修饰的白介素2、糖皮质激素和透明质酸用于治疗特应性皮炎

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756287A (fr) * 1969-09-17 1971-03-17 Hoechst Ag Produits de polyaddition d'ethylene-imines utilisables pour l'appretagede textiles
GB1361627A (en) * 1970-08-04 1974-07-30 Marumo H Detergent composition
IT956228B (it) * 1972-04-15 1973-10-10 Snia Viscosa Metodo ed additivi per conferire proprieta antistatiche a composi zioni poliammidiche e prodotti poliammidici ottenuti secondo tale metodo e con l impiego di tali additivi
US4520145A (en) * 1982-07-21 1985-05-28 The Boots Company Plc Modified thermosetting imide resins with improved fracture toughness
DE3730797A1 (de) 1987-09-14 1989-03-23 Siegel Rolf Materialien mit nicht-thrombogener oberflaeche
GB2215806B (en) 1988-02-15 1992-02-05 Hakko Co Method of applying a lining to a pipeline
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JPH0362814A (ja) * 1989-07-29 1991-03-18 Nisshinbo Ind Inc 親水性ポリカルボジイミドポリマー、該親水性ポリカルボジイミドポリマーによるパルプ状物及びそれらの製造方法
JP2902201B2 (ja) 1991-03-18 1999-06-07 ストックハウゼン ルイジアナ リミティド 超吸収性ポリマーの残留アクリル酸含量を低下させる方法
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5879923A (en) * 1995-06-26 1999-03-09 Daiichi Pure Chemicals Co., Ltd. Stable plasmin solution
CN1304058C (zh) * 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
CN1164533A (zh) 1997-01-09 1997-11-12 云南汉德技术发展有限公司 一种水溶性抗癌化合物-聚氨基酸紫杉醇酯
US6824766B2 (en) * 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU2001228742A1 (en) 2000-02-04 2001-08-14 Supratek Pharma, Inc. Ligand for vascular endothelial growth factor receptor
CN1125097C (zh) 2000-07-05 2003-10-22 天津大学 聚乙二醇支载的紫杉醇或多烯紫杉醇的前药
CN100475269C (zh) * 2002-03-05 2009-04-08 北京键凯科技有限公司 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途
JP4272537B2 (ja) * 2002-03-13 2009-06-03 北京鍵▲凱▼科技有限公司 Ｙ型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物
AU2003280592B2 (en) 2002-10-31 2008-12-18 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels

Also Published As

Publication number Publication date
JP2005520006A (ja) 2005-07-07
US20100221213A1 (en) 2010-09-02
EP1496076A1 (de) 2005-01-12
JP4272537B2 (ja) 2009-06-03
EP1496076B1 (de) 2007-07-25
CN1556828A (zh) 2004-12-22
US20110243892A1 (en) 2011-10-06
AU2003221291A1 (en) 2003-09-22
ATE368066T1 (de) 2007-08-15
DE60315145T2 (de) 2008-04-30
WO2003076490A8 (en) 2004-10-28
US8003089B2 (en) 2011-08-23
ES2291620T3 (es) 2008-03-01
US20050180946A1 (en) 2005-08-18
DE60315145D1 (de) 2007-09-06
CN1243779C (zh) 2006-03-01
WO2003076490A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
EP1496076A4 (de) Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff
EP1988910A4 (de) Acryloyloxyethylphosphorylcholin-haltige polymerkonjugate und ihre zubereitung
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
BRPI0520032A2 (pt) moléculas para transportar um composto através da barreira hematoencefálica
DE60001546D1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
BR0211227A (pt) Composto, composição farmacêutica e seus usos
BR9811818A (pt) Uso de um composto, composto, e, composição farmacêutica
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
ATE426635T1 (de) Arzneimittelverabreichung
EP1819227A4 (de) Pharmazeutische formulierungen von decitabin
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
ATE422356T1 (de) Pharmazeutische zubereitungen
DE60205905D1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2003080593A8 (en) Hydrophilic polymers-flavonoids conjugates and pharmaceutical compositions comprising them
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
DE60126046D1 (de) Bizyklische Amino-Pyrazon Derivate, deren Herstellung und pharmazeutische Zusammensetzungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20060522

RIC1 Information provided on ipc code assigned before grant

Ipc: C08G 65/00 20060101AFI20030925BHEP

Ipc: A61K 47/48 20060101ALI20060516BHEP

17Q First examination report despatched

Effective date: 20060905

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60315145

Country of ref document: DE

Date of ref document: 20070906

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: DR. GRAF & PARTNER INTELLECTUAL PROPERTY

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071025

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071226

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2291620

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071026

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071025

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

26N No opposition filed

Effective date: 20080428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080312

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: BEIJING JIANKAI TECHNOLOGY CO., LTD.

Free format text: BEIJING JIANKAI TECHNOLOGY CO., LTD.#BUILDING C-4F, SHANGDI XINXILU NO. 2, PIONEERING PARK, HAIDIAN DISTRICT#100085 BEIJING (CN) -TRANSFER TO- BEIJING JIANKAI TECHNOLOGY CO., LTD.#BUILDING C-4F, SHANGDI XINXILU NO. 2, PIONEERING PARK, HAIDIAN DISTRICT#100085 BEIJING (CN)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080312

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070725

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220324

Year of fee payment: 20

Ref country code: DE

Payment date: 20220322

Year of fee payment: 20

Ref country code: CH

Payment date: 20220324

Year of fee payment: 20

Ref country code: AT

Payment date: 20220318

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220323

Year of fee payment: 20

Ref country code: BE

Payment date: 20220322

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20220331

Year of fee payment: 20

Ref country code: ES

Payment date: 20220420

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60315145

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20230312

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20230311

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 368066

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230312

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230313